TrialThe Lancet. Oncology2017

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

William D Tap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.